Study of BCT301 for IgG4-related disease that has not responded to treatment
Part of Immune system & allergy clinical trials.
This study tests a new treatment for IgG4-related disease that has not improved with standard therapies. It aims to see if the treatment is safe and effective for people with active disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Are 18 to 75 years old
- Have a confirmed diagnosis of IgG4-related disease
- Have active disease affecting at least one organ (e.g., pancreas, kidneys, lungs)
- Have tried standard treatments like steroids or immunosuppressants and still have active disease
- Are currently on a stable dose of your medications
- Have not been treated with CD19 or BCMA targeted therapy or CAR-T cells before (unless it failed)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called ACE1831 for people with active IgG4-related disease that affects more than one organ. It aims to see if the drug can safely control the disease and reduce the need for steroids.
This trial tests whether a special type of immune cell therapy (CAR-T) can help people whose IgG4-related disease persists despite steroids or rituximab. It focuses on those with inflammation in two or more major organs.
This is a study that follows people diagnosed with IgG4-related disease to better understand the condition. It may help researchers confirm diagnoses and learn how the disease affects different organs over time.
This trial tests a new medicine called IMM0306 for IgG4-related disease, a condition where the immune system attacks multiple organs in your body. The study aims to see if IMM0306 can help control your disease and reduce flare-ups while using less steroid medication.
This trial tests a new treatment using immune cells (CAR-NK) designed to target and kill specific cells that may cause IgG4-related disease (IgG4-RD). It is for people whose IgG4-RD has come back or not responded to standard treatments.
This trial tests a short course of steroids combined with mycophenolate mofetil (MMF) for people with active IgG4-related disease who have not been treated before or whose disease came back after stopping treatment. The goal is to see if this combination helps control the disease better.
Hear when a new IgG4-Related Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.